Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab + ramucirumab in PD-L1 positive stage IB–IIIA NSCLC
jRCT2080224806Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and ramucirumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Center Hospital East. Started Jul 2019; status: completed.
02
Drugs
pembrolizumabramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224806.